Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02042430 · ClinicalTrials.gov registry record · Early Phase 1
Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Early Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Early Phase 1
- Development phase
- 17
- Enrollment target
NCT02042430: Completed Early Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT02042430 is a Early Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02042430, a Early Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This pilot Early Phase I clinical trial studies epacadostat before surgery in treating patients with newly diagnosed stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Epacadostat
- PROCEDURE Therapeutic Conventional Surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2014-08-25 |
| Est. Completion | 2016-11-29 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02042430
The ClinicalTrials.gov registry entry for NCT02042430 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02042430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02042430 about?
NCT02042430 is a clinical study titled "Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". This pilot Early Phase I clinical trial studies epacadostat before surgery in treating patients with newly diagnosed stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT02042430?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 17 participants. The study started on 2014-08-25. Estimated completion is 2016-11-29.
What interventions are being tested in trial NCT02042430?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Epacadostat (DRUG), Therapeutic Conventional Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT02042430?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.